Paying For Gene Therapy: Will Pharma Be First In Line?
Executive Summary
With 15 new gene and cell-based therapies in late-stage testing, the time is now to consider a critical strategic question: is there a pricing model for these budget-busting treatments that works in both safeguarding returns to innovators and providing access to patients at a price society is willing to pay? An analysis by ZS Associates looks at the options for biopharma going forward.
You may also be interested in...
CAR-T Reimbursement: Medicare Weighing Bundle For Kymriah, Yescarta In 2019
Otherwise, CMS proposes pegging inpatient hospital reimbursement for CAR-T treatment to bundled rate for bone marrow transplants and potentially providing add-on payments for at least a couple of years.